Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Konten disediakan oleh Proactive Investors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Proactive Investors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !
Offline dengan aplikasi Player FM !
Ananda Developments advances clinical trials, names Scientific Advisory Board
MP3•Beranda episode
Manage episode 447645439 series 2891889
Konten disediakan oleh Proactive Investors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Proactive Investors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Ananda Developments Finance Director Jeremy Sturgess-Smith joined Steve Darling from Proactive to share some of the key milestones achieved by the company in its interim results for February 1, 2024, to July 31, 2024. During this period, Ananda has advanced its patent-pending MRX1 CBD formulation in two fully funded Phase II trials for chemotherapy-induced nerve pain and endometriosis. Sturgess-Smith also noted the selection of Ananda's MRX2 and MRX2T CBD and CBD + THC formulations for two groundbreaking Phase III trials. These will be the world's first double-blind, randomized controlled trials (RCTs) to examine the combined use of CBD and THC for epilepsy, specifically challenging-to-treat cases in both children and adults. Conducted across multiple NHS sites, these trials aim to enroll 500 patients over 18 months to test the effects of CBD, a CBD/THC combination, and a placebo. Following the reporting period, Ananda's MRX1 CBD formulation will undergo a Phase I pharmacokinetic assessment. Additionally, preclinical studies on MRX1 have shown positive results for heart fibrosis treatment potential, part of the company’s efforts to establish a robust preclinical pipeline. To support these initiatives, Ananda completed a successful capital raise and announced the formation of a Scientific Advisory Board led by Professor Clive Page. #proactiveinvestors #anandadevelopmentsplc #aqse #ana #MRXFormulations #EpilepsyResearch #ClinicalTrials #HealthcareInnovation #CannabinoidResearch #NHS #Pharmaceuticals #Investing #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
611 episode
MP3•Beranda episode
Manage episode 447645439 series 2891889
Konten disediakan oleh Proactive Investors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Proactive Investors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Ananda Developments Finance Director Jeremy Sturgess-Smith joined Steve Darling from Proactive to share some of the key milestones achieved by the company in its interim results for February 1, 2024, to July 31, 2024. During this period, Ananda has advanced its patent-pending MRX1 CBD formulation in two fully funded Phase II trials for chemotherapy-induced nerve pain and endometriosis. Sturgess-Smith also noted the selection of Ananda's MRX2 and MRX2T CBD and CBD + THC formulations for two groundbreaking Phase III trials. These will be the world's first double-blind, randomized controlled trials (RCTs) to examine the combined use of CBD and THC for epilepsy, specifically challenging-to-treat cases in both children and adults. Conducted across multiple NHS sites, these trials aim to enroll 500 patients over 18 months to test the effects of CBD, a CBD/THC combination, and a placebo. Following the reporting period, Ananda's MRX1 CBD formulation will undergo a Phase I pharmacokinetic assessment. Additionally, preclinical studies on MRX1 have shown positive results for heart fibrosis treatment potential, part of the company’s efforts to establish a robust preclinical pipeline. To support these initiatives, Ananda completed a successful capital raise and announced the formation of a Scientific Advisory Board led by Professor Clive Page. #proactiveinvestors #anandadevelopmentsplc #aqse #ana #MRXFormulations #EpilepsyResearch #ClinicalTrials #HealthcareInnovation #CannabinoidResearch #NHS #Pharmaceuticals #Investing #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
611 episode
Semua episode
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.